Novartis received approval from the FDA for Extavia (interferon beta-1b) for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The drug is also indicated for patients who experience their first clinical episode of MS and have features consistent with the disease based on MRI results. “Novartis has been a leader in neuroscience for more than 50 years, having pioneered a number of breakthrough therapies which remain important treatments to this day,...